Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Epitope mapping of spike identifies variant-resistant antibodies


One of the biggest concerns in the ongoing COVID-19 pandemic is the potential emergence of SARS-CoV-2 variants that evade immunity. A report in Science now presents a comprehensive map of antibody binding sites of the SARS-CoV-2 spike protein, which was generated using several hundred monoclonal antibodies (mAbs). Among 186 mAbs targeted at the receptor binding domain (RBD) of spike, the authors (a global consortium) identified seven mAb communities with distinctive footprints and competition profiles. Using pseudovirion-based neutralization assays to test mAb binding to mutant spike proteins (with either individual mutations or combinations of mutations, including those corresponding to variants α–ε), they were able to identify key classes of RBD-targeted antibodies that maintained neutralization activity against these mutants. The study may allow to predict and interpret the effect of new mutations and inform the selection of antibody cocktails against new variants.


Original article

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Alexandra Flemming.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Flemming, A. Epitope mapping of spike identifies variant-resistant antibodies. Nat Rev Immunol 21, 693 (2021).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing